Page last updated: 2024-12-08

melibiose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

alpha-D-Galp-(1->6)-alpha-D-Glcp : A glycosylglucose consisting of alpha-D-galactopyranose and alpha-D-glucopyranose residues joined in sequence by a (1->6) glycosidic bond. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6602503
CHEBI ID151217
SCHEMBL ID11249703
MeSH IDM0013323

Synonyms (26)

Synonym
6-o-alpha-d-galactopyranosyl-d-glucose
melibiose ,
wurcs=2.0/2,2,1/[a2122h-1a_1-5][a2112h-1a_1-5]/1-2/a6-b1
alpha-d-galp-(1->6)-alpha-d-glcp
CHEBI:151217
gal(a1-6)a-glc
6-o-alpha-d-galactopyranosyl-alpha-d-glucopyranose
alpha-d-galacto-hexopyranosyl-(1->6)-alpha-d-gluco-hexopyranose
3ALT
DLRVVLDZNNYCBX-CQHUIXDMSA-N
SCHEMBL11249703
DTXSID90424933
220585-89-7
mlb
alpha-delta-melibiose
delta-melibiose
6-(a-d-galactosido)-d-glucose
delta-(+)-melibiose
6-(a-delta-galactosido)-delta-glucose
6-(d-galactosido)-d-glucose
6-o-a-d-galactopyranosyl-d-glucose
6-(d-galactosido)-delta-glucose
6-o-alpha-delta-galactopyranosyl-delta-glucose
alpha-melibiose
alpha-d-melibiose
Q27463256

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In 1 baboon, melibiose and arabinogalactan infusion delayed vascular rejection of a pig cardiac xenograft from 10 min to about 12 hr, at which time the baboon died from the toxic effects of the carbohydrate infusion."( Evidence that intravenously administered alpha-galactosyl carbohydrates reduce baboon serum cytotoxicity to pig kidney cells (PK15) and transplanted pig hearts.
Cooper, DK; Koren, E; Kosanke, S; Martin, M; Neethling, FA; Niekrasz, M; Oriol, R; Richards, SV; Ye, Y, 1994
)
0.29

Dosage Studied

ExcerptRelevanceReference
"1-kilobase fragment containing GAL4 by homologous complementation using the multicopy chimeric vector YEp24 and demonstrated that multiple copies of GAL4 in yeast have pronounced dosage effects on the expression of the structural genes."( Isolation of the yeast regulatory gene GAL4 and analysis of its dosage effects on the galactose/melibiose regulon.
Hopper, JE; Johnston, SA, 1982
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
glycosylglucose
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
stachyose biosynthesis523
melibiose degradation04

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Lectin CEL-IV, C-typeCucumaria echinataKd1,190.00001,190.00001,190.00001,190.0000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2011The Journal of biological chemistry, Mar-25, Volume: 286, Issue:12
Galactose recognition by a tetrameric C-type lectin, CEL-IV, containing the EPN carbohydrate recognition motif.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (315)

TimeframeStudies, This Drug (%)All Drugs %
pre-199080 (25.40)18.7374
1990's95 (30.16)18.2507
2000's69 (21.90)29.6817
2010's50 (15.87)24.3611
2020's21 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews12 (3.63%)6.00%
Case Studies1 (0.30%)4.05%
Observational0 (0.00%)0.25%
Other318 (96.07%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]